Rhabdomyolysis: a genetic perspective
Orphanet Journal of Rare Diseases volume 10, Article number: 51 (2015)
Rhabdomyolysis (RM) is a clinical emergency characterized by fulminant skeletal muscle damage and release of intracellular muscle components into the blood stream leading to myoglobinuria and, in severe cases, acute renal failure. Apart from trauma, a wide range of causes have been reported including drug abuse and infections. Underlying genetic disorders are also a cause of RM and can often pose a diagnostic challenge, considering their marked heterogeneity and comparative rarity.
In this paper we review the range of rare genetic defects known to be associated with RM. Each gene has been reviewed for the following: clinical phenotype, typical triggers for RM and recommended diagnostic approach. The purpose of this review is to highlight the most important features associated with specific genetic defects in order to aid the diagnosis of patients presenting with hereditary causes of recurrent RM.
Abstract in Portuguese
A rabdomiólise (RM) é um evento agudo e grave, caracterizado por danos do músculo esquelético com a liberação, em grande quantidade, de componentes intracelulares para a corrente sanguínea. Uma vasta gama de causas tem sido relatada, incluindo trauma, abuso de drogas e infecções. Doenças hereditárias também podem causar RM, mas muitas vezes representam um desafio diagnóstico, considerando a sua heterogeneidade e raridade. Por fim, diversas doenças neuromusculares costumam estar associadas com níveis de CK cronicamente elevados, dificultando a identificação correta dos episódios de RM.
Nesse artigo, revisamos os diversos defeitos genéticos associados à RM. Cada gene foi revisado abrangendo os seguintes: fenótipo clínico, gatilhos para RM e abordagem diagnóstica. O objetivo desta revisão é destacar as características mais importantes associados a defeitos genéticos específicos, a fim de auxiliar o diagnóstico de pacientes com causas hereditárias de RM recorrente.
Rhabdomyolysis (RM) is characterised by acute and often severe skeletal muscle damage resulting in the release of intracellular muscle components into the blood stream frequently resulting in myoglobinuria and, in severe cases, acute renal failure. Diverse etiologies (Figure 1) implicated in acute RM share a common final pathway, increased intracellular free ionized calcium, leading to muscle cell death through the activation of a number of detrimental mechanisms such as enzymatic activation and prolonged muscle fibre contraction [1,2]. Different genetic defects causing various neuromuscular and metabolic disorders are known to be associated with RM. Recurrent RM, exercise related complaints and a positive family history are common features of an underlying genetic condition. In some instances, RM may be due to a combination of genetic predisposition and environmental causes. In these cases a purely environmental factor may be considered the sole cause for the acute event with a relatively high risk of recurrence if the genetic diagnosis is not considered. Recently reported examples are a number of patients with “virally-induced” RM who in fact had malignant hyperthermia susceptibility (MHS)-associated RYR1 mutations, resulting in a genetic predisposition for the virally-triggered muscle breakdown [3,4].
Identifying underlying genetic disorders presenting with RM can pose a diagnostic challenge due to their rarity and marked heterogeneity, requiring a high degree of clinical suspicion for appropriate investigation to be requested. Although difficult, establishing a genetic diagnosis in a patient presenting with RM is of great clinical importance to give appropriate advice and to prevent future episodes. More recently Zutt et al. (2014) suggested an algorithm for the clinical diagnostic approach to recurrent RM  whereas the present review will focus on the approach to a specific genetic diagnosis. Here we review the genetic defects known to be associated with RM, many of them are rare and very rare (summarized in Table 1). The purpose of this review is to highlight the most important features in order to aid the genetic diagnosis of patients with unexplained, in particular recurrent RM episodes (Figures 2 and 3).
Inherited metabolic disorders of skeletal muscle are rare conditions that can be divided into those disorders caused by abnormal glycogen storage affecting muscle and disorders of fatty acid oxidation. In metabolic myopathies, exploring patients’ symptoms in relation to the timing and type of exercise will provide a strong clinical clue. The other clue to a metabolic diagnosis is that symptoms are experienced in all skeletal muscles including, neck, jaw, arms, paraspinals and legs. In disorders of glycogenolysis (such as McArdle disease) and glycolysis (such as Tarui disease) symptoms are induced within minutes by isometric muscle contraction (such as weight lifting), intense maximal exercise (such as sprinting) or within a few minutes of aerobic physical activity (such as walking). By contrast, in disorders of fatty acid metabolism symptoms occur only after aerobic exercise for a more prolonged period (over 45 minutes and often after several hours). In addition, fever, fasting and stress can induce symptoms. Symptoms are not triggered by isometric contraction in people with fatty acid metabolism dysfunction. Thus, a detailed medical history with careful consideration of the precipitating factors is essential for the correct diagnosis to be made. However, phenotypic variations do exist, for example in glycogen storage disorder type XIV, caused by recessive mutations in PGM1, where additional dysmorphic and systemic features such as bifid uvula, cleft palate, liver disease and growth retardation are prominant (outlined in more detail below) . Recognising both the general symptoms of metabolic myopathies and the specific phenotypic variations of specific genetic defects is essential to guide further investigations.
Thus, despite recent advances in the genetic diagnosis, a detailed targeted medical history remains the most important initial step for identifying the underlying inherited metabolic causes of RM and to aid choice of invasive diagnostic investigations such as skin (in suspected fatty acid oxidation disorders) and muscle biopsy, for tissue histochemistry and/or biochemical analysis (in suspected glycogen storage disorders). In the majority of these conditions, inheritance is autosomal-recessive, with only few conditions inherited in an X-linked, autosomal-dominant or mitochondrial fashion.
Disorders of glycogen metabolism
A variety of enzymes are involved in glycogen metabolism, an important energy source for skeletal muscle during isometric, anaerobic exercise, aerobic glycolysis and strenuous exertion. Genetic defects leading to absence or severe deficiency of these enzymes cause impaired glycogen breakdown, resulting in exercise intolerance and RM. In addition, in some of these glycogen storage disorders (GSDs) enzymes are expressed in tissues other than skeletal muscle, leading to other clinical manifestations such as haemolytic anaemia, brain and skin involvement. A feature of these conditions is a suboptimal rise in lactate during exercise and exaggerated rise in ammonia in McArdle disease. Diagnosis is dependent upon biochemical analysis of muscle tissue which reveals the reduced enzyme activity. Diagnosis is confirmed by genetic studies.
McArdle disease (GSDV) is the most common disorder in this group, and it will therefore be reviewed in more detail. Other types of GSDs are extremely rare and their features will only be briefly summarized.
Muscle Glycogen Phosphorylase (PYGM)
Homozygous or compound heterozygous mutations in PYGM (OMIM #608455) cause glycogen storage disease type V (GSDV, McArdle disease) which is characterized by the absence of skeletal muscle glycogen phosphorylase, resulting in an inability to convert muscle glycogen into glucose-1-phosphate [6,7]. As a result, glycogen accumulates in skeletal muscle.
Exercise intolerance presenting as muscle fatigue, discomfort and cramps within minutes of exertion, commonly associated with a disproportionate increased in heart rate (HR) [8,9]. Symptoms are more severe with strenuous exercise such as climbing stairs or walking up hills and isometric contraction (heavy lifting or squatting) . Prolonged muscle spasm (muscle contracture) is not uncommon and can lead to RM. The second wind phenomenon is characterized by symptoms easing and an associated decrease in HR leading to an improvement in exercise tolerance occurring at around 8–10 minutes of aerobic exertion. It is the hallmark of this condition and is due to improved blood flow resulting in improved availability of glucose release from the hepatic glycogen stores and fatty acid oxidation metabolism . Other clinical features may include muscle hypertrophy. Fixed weakness predominantly affecting shoulder girdle and axial (paraspinal) muscles is another feature of GSDV usually seen in older patients [9,10]. GSDV symptoms usually begin during early childhood but patients often experience several episodes of myoglobinuria and RM before the diagnosis is confirmed .
Triggers for Rhabdomyolysis
Persistent skeletal muscle activity despite symptoms (before getting into the second wind phenomenon), intense exertion, anaerobic activity, isometric contraction and sustained muscle contracture [13,14].
Serum CK is almost always raised, often >1,000 IU/L. Muscle biopsy shows subsarcolemmal vacuoles with glycogen accumulation and the absence (or virtual absence in rare cases) of muscle glycogen phosphorylase activity demonstrated by muscle histochemistry and/or muscle biochemical enzyme analysis . Functional testing using either cycle test or 12 minute walk test can be used to demonstrate the presence of the second wind phenomenon . Forearm exercise test shows suboptimal (<3 fold) increase in serum lactate with a normal rise in ammonia . Non-ischaemic exercise test is preferred because of the risk of contracture and compartment syndrome in people with McArdle disease.
Phosphofructokinase, Muscle Type (PFKM)
Autosomal-recessive mutations in the PFKM gene (OMIM #610681) cause GSD type VII, or Tarui’s disease, a metabolic myopathy characterized by phosphofructokinase (PFK) deficiency resulting in impaired conversion of fructose-6-phosphate to fructose-1.6-diphosphate, affecting both anaerobic and aerobic glycolysis. In general, GSDVII shares similar presentation with GSDV (see above) except that GSDVII presents with more severe exercise intolerance.
Similar to GSDV but there is no second wind phenomenon. In fact, unlike GSDV where oral administration of glucose immediately prior to exercise can improve exercise tolerance, in Tarui disease it exacerbates exercise intolerance leading to an ‘out-of-wind phenomenon’ by impairing fatty acid oxidation . Atypical variants reported include severe infantile form with arthrogryposis, a form presenting with fixed myopathy and haemolytic anaemia without muscle symptoms. Hypertrophic cardiomyopathy has been reported in one patient [15,18-20].
Triggers for Rhabdomyolysis
Exercise and isometric muscle contraction .
The combination of haemolytic anaemia and myopathy should raise the suspicion of GSDVII [18,20]. The combination of haemolytic anaemia and muscle symptoms can also be associated with GSDXII and phosphoglycerate kinase deficiency described below. Serum CK is usually raised and forearm exercise test reveals a suboptimal increase in lactate. As in McArdle disease, hyperuricaemia and gout are more frequent. Muscle biopsy shows a vacuolar myopathy with polyglucosan accumulation demonstrated by positive periodic acid-Schiff (PAS) staining but resistant to diastase digestion  and weak/negative PFK histochemistry [15,18,20]. Enzyme biochemical analysis shows reduced enzyme activity in muscle and, in some patients, in erythrocytes .
Aldolase A, Fructose-bisphosphate (ALDOA)
GSDXII or aldolase A deficiency is a very rare metabolic disorder characterized by the deficiency of the aldolase A isoform which converts fructose 1,6-biphosphate into dihydroxyacetone phosphate and glyceraldehydes 3-phosphate. As a result, glycolysis is affected in muscle and erythrocytes. GSDXII is caused by autosomal-recessive mutations in the ALDOA gene (OMIM #103850).
Non-spherocytic haemolytic anaemia. Rare cases with myopathic manifestations including muscle pain and weakness, exercise intolerance and RM [21,22]. RM may be seen during the first months of life .
Triggers for Rhabdomyolysis
Reduced red blood cell aldolase in combination with high serum CK suggest the diagnosis [22,25]. Muscle biochemistry shows reduced aldolase activity . The spectrum of histopathological findings in GSDXII and their clinical relevance are currently unclear. In one patient the following pathological features were reported: variation in fibre size, split fibres and increased activity of acid phosphatase. Electron microscopy (EM) revealed accumulation of lipid, increased variation in mitochondrial size and shape, variation in myofibrilar diameter and increased intermyofibrillar space . The presence of lipid droplets accumulation in oil-red-O histochemistry was reported in another patient . Diagnosis is confirmed by finding homozygous or compound heterozygous mutations in ALDOA.
Beta Enolase 3 (ENO3)
Autosomal-recessive mutations in the ENO3 gene (OMIM #131370) cause GSD XIII or muscle β-enolase deficiency. β-enolase is a distal glycolytic enzyme.
Triggers for Rhabdomyolysis
Strenuous exertion and isometric muscle activity .
CK may be normal or mildly raised between attacks of RM. Forearm exercise test shows a suboptimal increase in serum lactate . Muscle biopsy examination under light microscopy may be unremarkable while EM may show glycogen accumulation [26,27]. Biochemical analysis of muscle tissue shows severely reduced activity of β –enolase [26,27]. Diagnosis is confirmed by genetic studies.
Phosphoglycerate Mutase 2 (PGAM2)
Autosomal-recessive mutations in the PGAM2 gene (OMIM #612931) cause GSD type X, a metabolic myopathy characterized by the reduction of muscle phosphoglycerate mutase (PGAM) resulting in a terminal block in glycogenolysis. A mild residual activity of the brain isoform of the enzyme may be detected in muscle tissue.
Triggers for Rhabdomyolysis
Serum CK is usually raised. Forearm exercise test may show a mild suboptimal raise in lactate [18,31]. Biochemical analysis of muscle tissue shows reduced enzyme activity . Muscle biopsy may show tubular aggregates [28,29] and glycogen accumulation . Thus the triad of exercise-induced cramps, recurrent myoglobinuria and tubular aggregates on muscle biopsy should alert the clinician to the possibility of PGAM deficiency .
Phosphoglycerate Kinase 1 (PGK1)
Phosphoglycerate kinase 1 (PGK) deficiency (OMIM #300653) is an X-linked disorder characterized by the reduction of phosphoglycerate kinase 1, which catalyses the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate.
Marked clinical variability has been described, including haemolytic anaemia, muscle cramps and myalgia, weakness, increased serum CK levels, exercise intolerance, RM and central nervous system (CNS) manifestations including mental retardation and development delay [33-36].
Triggers for Rhabdomyolysis
Serum CK may be raised or within normal range. Full blood count showing reticulosis and mildly raised serum bilirubin may suggest haemolysis. Forearm exercise test shows suboptimal rise in lactate with exaggerated rise in ammonia [35,36]. Muscle biopsy findings may be unremarkable [33,36] or show minor changes such as fibre atrophy . EM may reveal glycogen accumulation [35,37]. Biochemical analysis shows decreased PGK enzyme activity in muscle, erythrocytes [35-37], white cells and platelets .
Phosphoglucomutase 1 (PGM1)
Recessive mutations in PGM1 (OMIM #171900) cause GSD type XIV or phosphoglucomutase 1 deficiency, a clinically heterogeneous multisystem disorder with features of a metabolic disorder and a congenital disorder of glycosylation .
A recent study reviewed the clinical phenotype of GSDXIV . Reported symptoms include endocrine disorders, liver disease, bifid uvula, cleft palate, growth retardation, hypogonadic hypogonadism, hypoglycaemia and cardiomyopathy. Muscle symptoms include exercise intolerance, weakness and RM . Bifid uvula and liver disease were the most common features recently reported by Tegtmeyer et al. (2014) .
Triggers for Rhabdomyolysis
Strenuous exercise [5,38]. Malignant hyperthermia and RM were reported in one patient after halothane administration . The combination of propofol and remifentanil caused mild raised CK in the same patient .
Serum CK may be raised. Serum transferrin isoforms are abnormal . Incremental exercise test until exhaustion on a cycle ergometer may show normal elevation of serum lactate levels . Muscle biopsy may show glycogen accumulation and reduction of phosphoglucomutase activity on biochemical evaluation .
Phosphorylase Kinase, Muscle, Alpha-1 Subunit (PHKA1), Phosphorylase Kinase, Liver, Alpha-2 Subunit (PHKA2), Phosphorylase Kinase, Beta Subunit (PHKB), Phosphorylase Kinase, Testis/Liver, Gamma-2 (PHKG2)
Mutations in the PHKB, PHKA1, PHKA2, PHKG2 genes (encoded by chromosome 16, X, X and 16 respectively) cause GSD type IX, characterized by the deficiency of phosphorylase kinase (PK) resulting in impairment of glycogen metabolism. PK has four subunits differentially expressed in different tissues and encoded by different genes. Symptomatic muscle PK deficiency may be seen in association with PHKB (OMIM #172490) and PHKA1 (OMIM #311870) mutations, although a mild transitory form of muscle weakness and myalgia after strenuous exertion has been recently reported in two patients with PHKG2 mutations . The phosphorylation of phosphorylase b into its active form (phosphorylase a) is catalysed by the PK . Thus muscle symptoms of GSDIX shares similar symptoms with GSDV, but they are usually milder. Here we will focus on mutations in PHKB and PHKA1 which are known to affect the skeletal muscle isoform.
Hepatomegaly, hypoglycemia following fasting and growth delay are the primary presenting symptoms of mutations in PHKB , although mild muscle symptoms occur. Muscle symptoms associated with mutations in PHKA1 are usually mild and include exercise-induced myalgia and cramps, fatigue and myoglobinuria [43,44]. Raised CK following statin use was reported in association with PHKA1 in one patient .
Triggers for Rhabdomyolysis
Serum CK may be raised in between episodes of RM . Muscle histology may show nonspecific abnormalities and free glycogen accumulation [43,46]. PK activity is reduced in muscle. Reduced enzyme activity in erythrocytes may be seen but normal values do not exclude the condition. Forearm exercise test may show an exaggerated increase in ammonia but a normal lactate response .
Disorders of fatty acid metabolism
Lipids are an important energy source of skeletal muscle during endurance exercise, recovery following physical exertion and when at rest. Different enzymes participate in long-chain fatty acid breakdown in mitochondria. Beta-oxidation of long chain fatty acids differs from mitochondrial disorders, where primary downstream effect usually directly impair oxidative phosphorylation, ultimately reducing ATP production as described below (mitochondrial disorders section). Defects in the beta-fatty acid oxidation pathway lead to disorders of fatty acid metabolism, frequently characterized by exercise intolerance, muscle pain and episodes of RM related to prolonged aerobic exercise and other triggers such as fever, fasting, stress, drugs (such as sodium valproate and statins) and certain anaesthetic drugs. RM may also be related to exertion when resumed after rest following the onset of symptoms.
Propofol Infusion Syndrome (PIS) is a rare condition following the administration of high doses of propofol. Symptoms include a wide range of systemic complications such as cardiovascular, respiratory, metabolic, and hepatic dysfunction . RM may be seen in association with PIS. Young age, high dose of propofol, concomitant administration of vasopressor and underlying critical illness are considered risk factors for PIS. Inborn errors of mitochondrial fatty acid oxidation have been listed as risk factors for PIS  although the pathogenic mechanism is not fully understood.
ACYL-CoA Dehydrogenase, Very long-chain (ACADVL)
Homozygous or compound heterozygous mutations in the ACADVL gene (OMIM #609575) cause a metabolic myopathy due to very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, an enzyme associated with the inner mitochondrial membrane that plays an important role in the first step of mitochondrial long chain fatty acid oxidation.
Varies in severity depending upon age of presentation and includes three main clinical presentations: 1) severe neonatal/early-childhood onset form presenting with cardiomyopathy, hepatic disease and hypotonia with high mortality in infancy, 2) milder childhood onset form with hypoketotic hypoglycaemia, hypotonia with or without hepatic disease and 3) adult-onset form presenting with exercise intolerance, muscle cramps and RM [48,49]. However, there may be some symptom overlap between the three clinical forms and RM has also been reported in the mild childhood onset form  which may evolve into an adult onset phenotype with age. Patients presenting with the adult-onset form may have symptoms between episodes of RM . Severity and genotype may be correlated, corresponding to the mutation-dependent level of the residual enzyme activity (for example, severe early-childhood onset form with no residual enzyme activity is associated with the homozygous R429W mutation) .
Triggers for Rhabdomyolysis
Serum CK may be normal or raised between attacks and may vary considerably between separate measurements. Muscle biopsy is unhelpful and should not be performed if VLCAD is suspected, instead the most important first line investigation is fasting blood acyl-carnitine profile which shows accumulation of long-chain acyl-carnitines usually with prominent C14:1. Functional testing of fatty acid oxidation studies in skin fibroblasts is abnormal. Diagnosis is confirmed by finding homozygous or compound heterozygous mutations in ACADVL.
Carnitine Palmitoyltransferase II (CPT2)
Autosomal-recessive mutations in the CPT2 gene (OMIM #600650) cause carnitine palmitoyl-transferase-II (CPT-II) deficiency, the most common disorder of fatty acid oxidation. CPT-II deficiency is characterized by reduced or absent enzyme activity depending on the genotype.
The clinical phenotypes are very similar to VLCAD deficiency with three main forms: 1) fatal neonatal form presenting with dysmorphic features, severe skeletal and cardiac muscle involvement, 2) infantile-onset form with hepatic, cardiac and skeletal muscle involvement with hypoketotic hypoglycemia and 3) late (juvenile or adult) onset with myalgia, exercise intolerance and recurrent RM [52-54]. Importantly, enzyme defect and a more severe phenotype have been correlated with certain genotypes (for example, homozygous p.R631C and heterozygous null mutations in trans with a second mutation) .
Triggers for Rhabdomyolysis
Prolonged exercise, fever, heat shock, infection, high fat intake, fasting, exposure to cold, emotional stress, drugs including sodium valproate and statins  and lipid soluble intravenous anaesthetic drugs . A malignant hyperthermia-like syndrome was described in association with the heterozygous (R503C) mutation following succinylcholine and halothane administration .
As with VLCAD, CK may be normal in between episodes and muscle biopsy is not helpful and should not be performed if CPT-II deficiency is suspected. Fasting blood acyl-carnitine profile may show accumulation of long-chain acyl-carnitines usually with prominent C16, C18:1, C18 and is the preferred first line investigation. Enzyme activity may be assessed in muscle tissue, platelets/leukocyte and skin biopsy (cultured fibroblasts). Diagnosis is confirmed by finding mutations in CPT2, however approximately 60% of affected people carry the common (c.338C > T, p.Ser113Leu): thus, testing of this specific mutation is recommended as a second line investigation .
Electron Transfer Flavoprotein, Alpha Polypeptide (ETFA), Electron Transfer Flavoprotein, Beta Polypeptide (EFTB), Electron Transfer Flavoprotein Dehydrogenase (ETFDH)
Autosomal-recessive mutations in the EFTA (OMIM #608053), EFTB (OMIM #130410) and ETFDH genes (OMIM #231675) cause glutaric aciduria type II (GAII or multiple acyl-coenzyme A dehydrogenase deficiency), a metabolic condition characterized by the deficiency of the alpha or beta subunits of electron transfer flavoprotein or the electron transfer flavoprotein dehydrogenase. GAII results in a metabolic disturbance usually associated with acidosis due to the inability to breakdown fatty acids (mitochondrial fatty acid oxidation) and amino acids to generate energy. Choline metabolism is also affected. As a result, metabolism and excretion of organic acids such as glutaric acid are impaired.
May vary according to age of presentation with essentially three main forms: 1) neonatal-onset form presenting with hypotonia, hepatomegaly, hypoglycaemia and metabolic acidosis in association with congenital abnormalities such as dysmorphism and polycystic kidneys and high mortality in infancy, 2) neonatal-onset form with no congenital abnormalities and 3) late-onset form presenting with a wide spectrum of symptoms including myopathy, metabolic acidosis and hypoglycaemia [52,57]. Muscle symptoms include myalgia, weakness, exercise intolerance and RM [57-61]. Muscle weakness may respond to riboflavin given orally. Cardiomyopathy may be seen in all forms .
Triggers for Rhabdomyolysis
Reported triggers for RM are physical exercise, fasting, irregular diet or infection . Triggers for metabolic decompensation may also include sodium valproate therapy, weight loss, alcohol intake and febrile illness .
Increased fasting urine organic acids (glutaric acid, ethylmalonic acid, isovaleric acid, a-methylbutyrate, isobutyrate, aliphatic dicarboxylic acids, and their derivatives) and plasma acyl-carnitine profile (increased C4-C12) may confirm the diagnosis when evaluated during a metabolic stress episode . Plasma free carnitine level may be decreased . Muscle biopsy may show lipid accumulation and enlarged mitochondria [15,57,58].
Mitochondria are highly dynamic organelles that provide cellular energy, in the form of adenosine triphosphate (ATP), via oxidative phosphorylation. Since skeletal muscle tissue has very high energy requirements, it is particularly sensitive to impaired mitochondrial function.
Mitochondrial diseases usually refer to genetic defects whose primary downstream effect directly impairs oxidative phosphorylation which ultimately reduces ATP production. However, a number of additional essential metabolic processes occur within mitochondria, such as beta-oxidation of long chain fatty acids. Mutations in genes encoding enzymes involved with beta-oxidation disrupt mitochondrial fatty acid oxidation and include CPT-II and VLCAD deficiency, both of which are discussed above.
The clinical presentation of mitochondrial disorders is extremely variable. This is, in part, due to the large number of genetic causes implicated in the development of disease. One important, although relatively infrequent, manifestation of mitochondrial disease is RM. Table 1 summarizes a few examples of genes associated with mitochondrial dysfunction and RM.
Multisystem features vary according to the genetic mutation and may include cardiomyopathy, liver disease, Leber hereditary optic neuropathy, bowel dysmotility, Leigh syndrome, developmental delay and mental retardation. Muscle symptoms may include myopathy, fatigue, exercise intolerance, myalgia, limb and facial weakness, recurrent RM episodes and muscle cramps [62-71].
Triggers for Rhabdomyolysis
Physical activity/exercise and viral illness have been associated with RM, although often it may not be possible to identify a specific trigger [64,66,67,69,71]. Mitochondrial dysfunction has been considered to play an important role in PIS (see above, disorders of fatty acid metabolism section), although the pathogenic mechanisms of PIS are not fully understood yet. PIS has been recently associated with Leber hereditary optic neuropathy  and POLG1  although the reported patients had more than one risk factor for PIS. Further studies are needed to confirm a genetic predisposition for PIS.
Serum CK may be normal or raised. In one patient acyl-carnitine profile mimicked acyl-CoA dehydrogenase deficiency in COII mutation (m.8156dupG mutation) . Raised serum lactate may be seen at rest and following exercise [63,64]. Muscle biopsy may reveal ragged red fibres, cytochrome c oxidase (COX)-negative fibres and subsarcolemmal accumulation of mitochondria. Ragged red fibres staining positive for COX and succinate dehydrogenase (SDH) may be seen in association with a cytochrome b gene defect [63,64]. Reduced SDH activity, patchy COX deficiency, iron accumulation and ultrastructurally abnormal mitochondria containing electron dense inclusions have been associated with iron-sulfur cluster assembly enzyme [15,67]. Nonspecific myopathic features may be seen. Analysis of respiratory chain enzymes may help the diagnosis. First line investigation for mtDNA common mutations may be performed in a blood sample but usually skeletal muscle is required to sequence mtDNA for cases presenting with RM.
Disorders of intramuscular calcium release and excitation-contraction coupling
Excitation-contraction coupling (ECC), i.e. the effective translation of an electrical neuronal impulse into muscle contraction, is an intricate process involving several intramuscular ion channels and pumps. The key players involved in ECC are the voltage-gated dihydropyridine receptor localized on the transverse tubules, the ligand-gated skeletal muscle ryanodine receptor (RyR1) localized on the sarcoplasmic reticulum, and various sarcoendoplasmic reticulum (SR) calcium transport ATPases (SERCAs). Although neuromuscular phenotypes have been associated with all 3 proteins, RYR1-related neuromuscular disorders are by far the most common and may also feature RM episodes.
Ryanodine Receptor 1 (RYR1)
Mutations in the RYR1 gene (OMIM#180901) cause a wide spectrum of neuromuscular phenotypes, ranging from the dominantly inherited MHS trait  to various congenital myopathies, including dominantly inherited Central Core Disease  and subgroups of recessively inherited Multi-minicore Disease , Centronuclear Myopathy  and Congenital Fibre Type Disproportion . RYR1 encodes the principal SR calcium release channel with a crucial role in skeletal muscle excitation-contraction (E-C) coupling.
A wide range of neuromuscular features may be seen in association with RYR1 mutations, including hypotonia, developmental delay, facial weakness with or without ptosis and extraocular muscle involvement, axial and proximal muscle weakness. However, RYR1-related (exertional) rhabdomyolysis occurs mainly in individuals with MHS-associated RYR1 mutations who rarely exhibit any muscle weakness, but rather on the contrary, may exhibit muscle hypertrophy and even superior athletic abilities. In addition to exertion-induced RM, myalgia, muscle stiffness and heat intolerance are common in this group of patients [3,75]. King-Denborough syndrome and late-onset axial myopathy are other myopathic manifestations closely associated with MHS-related RYR1 mutations [79,80].
Triggers for Rhabdomyolysis
Heat, exercise, anaesthetic (MHS), muscle relaxants (MHS), drugs and alcohol but not fasting. Exercise is the most common trigger, but often a combination of factors appears to be required to trigger an episode [3,81]. In contrast to some of the metabolic conditions outlined above, RM episodes events may occur hours (occasionally days) after intense and unaccustomed exercise. Infection may unmask MHS-related RYR1 mutations [3,4] and may be an underdiagnosed cause of RYR1-related rhabdomyolysis.
Muscle pathology findings may vary. A recent review of patients presenting with rhabdomyolysis due to (mainly MHS-associated) dominant RYR1 mutation showed that muscle biopsy findings were often non-specific, but may feature “RYR1-compatible” findings including irregular internal architecture or core-like structures, increased internal nuclei, type 1 fibre predominance and pinprick fibres expressing neonatal myosin . Muscle magnetic resonance imaging (MRI) findings in the same cohort often showed marked muscle hypertrophy corresponding to clinical features , but not the pattern of selective involvement typically seen in RYR1-associated congenital myopathies , in keeping with the divergent clinical phenotypes.
Muscular dystrophies (MD) represent a clinically and genetically heterogeneous group of disorders characterized by progressive weakness and skeletal muscle degeneration. There is an increased susceptibility for muscle damage and RM may be seen in association with exertion but the timing of onset of symptoms with duration of exercise is often vague. Exertion muscle symptoms and myoglobinuria may be the presenting symptom of an underlying MD even before weakness becomes clearly manifest . Becker muscular dystrophy (BMD) due to mutations in DMD and limb-girdle muscular dystrophy 2I (LGMD2I) due to mutations in FKRP (OMIM#606596) are the most common dystrophies to present with RM . RM and myalgia may be the dominating symptom in a few cases of LGMD2I . RM as the presenting symptom of MDs has also been reported in association with sarcoglycanopathies, dysferlinopathies [83,84] and the more recently reported conditions related to recessive mutations in ANO5. Recessive mutations in ANO5 (OMIM#608662) cause a wide spectrum of myopathies including LGMD2L, distal myopathy and isolated hyperCKemia. Exercise intolerance, severe myalgia, variable muscle weakness and RM have been associated with ANO5 [85,86], although specific triggers for RM could not be elicited . Identification of amyloid deposition on muscle biopsy is a clue for the diagnosis of an anoctaminopathy [85,86]
Thus, unexplained RM occurring in the context of a history of exertion myalgia should also raise the suspicion of MDs, even if no weakness is clearly manifest. Figure 1 and Table 1 summarises the main MDs associated with RM [8,83,85-90].
Autosomal-recessive mutations in the LPIN1 gene (OMIM #605518) have been reported as the second most common cause of early-onset RM . Impaired lipid synthesis of triglycerides and membrane phospholipids as well as energetic defect have all been hypothesised as pathogenic mechanisms for RM in this disorder, although the exact mechanism remains unclear .
Early onset usually before 6 years with a mean age of onset of approximately 21 months [91,92] with severe episodes of RM with high mortality [92,93]. Myalgia and stiffness may be seen during acute episodes of RM . Episode frequency may decrease with age .
Triggers for Rhabdomyolysis
Between episodes serum CK and acyl-carnitine profile may be normal. Muscle biopsy can be normal or it can show lipid accumulation. Type I fibre predominance, type II fibre atrophy and ragged-red fibres have been reported [15,91,94]. Genetic testing is required to confirm the diagnosis.
SIL1, S. Cerevisiae, Homolog Of (SIL1)
Autosomal-recessive mutations in SIL1 (OMIM #608005) cause Marinesco-Sjogren syndrome, a multisystem disorder with consistent neuromuscular involvement.
Cataracts, cerebellar atrophy and ataxia are usually seen in association with different multisystem signs and symptoms. Neuromuscular findings include hypotonia, development delay, weakness, a variably associated peripheral neuropathy, and, rarely, RM [15,95,96].
Triggers for Rhabdomyolysis
Muscle biopsy may show a broad spectrum of myopathic features including rimmed vacuoles, increase in connective tissue with fat infiltration, ragged red fibres and type I fibre predominance. EM may show unique dense membranes/tubules surrounding the muscle fibre nucleus .
tRNA Splicing Endonuclease 54, S. Cerevisiae, Homolog Of (TSEN54)
Pontocerebellar hypoplasia type 2 (PCH-2) is a neurodegenerative disorder characterized by hypoplasia and atrophy of pons and cerebellum in association with other CNS manifestations. Recent reports suggest a myopathic component in PCH-2, including RM that has been reported in association with mutations in the TSEN54 gene (OMIM #608755).
Triggers for Rhabdomyolysis
Brain MRI may confirm the CNS abnormalities. Muscle biopsy may be normal or show fibre atrophy on light microscopy. EM may show abnormalities including sarcomeric disruption and Z-band abnormalities even in patients where light microscopy is normal .
Genetic Polymorphisms and association with RM
In addition to the genetic conditions detailed above, different genetic polymorphisms have already been associated with CK elevations, however it is not entirely clear if the same polymorphisms also confer a higher risk for RM, as contradictory findings have been reported. One example of such contradiction is the I allele in the angiotensin I-converting enzyme (ACE) gene which has been previously associated with increased CK levels after eccentric exercise by Yamin et al. (2007) but not by other authors [100-102]. The same has been observed with the R577X ACNT3 variant: the XX genotype, which has been reported in athletes , was also associated with low muscle strength and low resting CK  and exertional RM .
These intriguing findings emphasise the complexity of RM pathophysiology and the need for further studies to clarify the role of polymorphisms in muscle breakdown. Table 2 summarises a few genetic polymorphisms previously reported in association with CK elevations and muscle symptoms [100-102,104-107].
Inherited muscle disorders associated with RM are heterogeneous and rare. Much of the current knowledge concerning these conditions is based on individual case reports. Within the group of inherited muscle disorders, RM occurs most frequently in disorders of muscle metabolism (most commonly due to mutations in ACADVL, CPT2 and PYGM), mitochondrial dysfunction, muscular dystrophies (most commonly seen in BMD and LGMD2I), congenital myopathies where intracellular calcium homeostasis and excitation-contraction coupling are affected (RYR1) and LPIN1. Awareness of specific genotype-phenotype correlations in genetic conditions associated with RM is of importance to inform the diagnostic approach. In individual cases, RM events may reflect a combination of a genetic predisposition and environmental triggers, and the presence of an identifiable trigger does not necessarily exclude an underlying genetic cause.
A substantial proportion of patients presenting with RM remain currently genetically unsolved, suggesting additional pathogenic mechanisms not yet discovered. Polymorphisms causing an additive effect in the pathogenesis of RM have been suggested by different authors but may prove difficult to confirm. New diagnostic techniques such as next generation sequencing and whole exome/genome sequencing may help to evaluate patients for comprehensive gene sets concomitantly as well as identifying new genetic causes of RM [108,109].
Becker muscular dystrophy
Central nervous system
Cytochrome c oxidase
Glutaric aciduria type II
Glycogen storage disorder
Limb-girdle muscular dystrophy 2I
Malignant hyperthermia susceptibility
Magnetic resonance imaging
Pontocerebellar hypoplasia type 2
Propofol infusion syndrome
Skeletal muscle ryanodine receptor
Very long-chain acyl-CoA dehydrogenase
Chatzizisis YS, Misirli G, Hatzitolios AI, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19(8):568–74.
Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJ, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord. 2014;24(8):651–9.
Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, Drost G, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord. 2013;23(7):540–8.
Molenaar JP, Voermans NC, van Hoeve BJ, Kamsteeg EJ, Kluijtmans LA, Kusters B, et al. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Intern Med J. 2014;44(8):819–20.
Tegtmeyer LC, Rust S, van Scherpenzeel M, Ng BG, Losfeld ME, Timal S, et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med. 2014;370(6)):533–42.
Andreu AL, Nogales-Gadea G, Cassandrini D, Arenas J, Bruno C. McArdle disease: molecular genetic update. Acta Myol. 2007;26(1):53–7.
Vieitez I, Teijeira S, Fernandez JM, San Millan B, Miranda S, Ortolano S, et al. Molecular and clinical study of McArdle’s disease in a cohort of 123 European patients. Identification of 20 novel mutations. Neuromuscul Disord. 2011;21(12):817–23.
Quinlivan R, Jungbluth H. Myopathic causes of exercise intolerance with rhabdomyolysis. Dev Med Child Neurol. 2012;54(10):886–91.
Quinlivan R, Buckley J, James M, Twist A, Ball S, Duno M, et al. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry. 2010;81(11):1182–8.
Nogales-Gadea G, Arenas J, Andreu AL. Molecular genetics of McArdle’s disease. Curr Neurol Neurosci Rep. 2007;7(1):84–92.
Braakhekke JP, de Bruin MI, Stegeman DF, Wevers RA, Binkhorst RA, Joosten EM. The second wind phenomenon in McArdle’s disease. Brain. 1986;109(Pt 6):1087–101.
Scalco RS, Chatfield S, Godfrey R, Pattni J, Ellerton C, Beggs A, et al. From exercise intolerance to functional improvement: the second wind phenomenon in the identification of McArdle disease. Arq Neuropsiquiatr. 2014;72(7):538–41.
Brady S, Godfrey R, Scalco RS, Quinlivan R. Emotionally-intense situations can result in rhabdomyolysis in McArdle disease. BMJ Case Rep, 2014.
Lucia A, Nogales-Gadea G, Pérez M, Martín MA, Andreu AL, Arenas J. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4(10):568–77.
Goebel H, Sewry C, Weller R. Muscle disease: pathology and genetics. 2nd ed. London: Wiley-Blackwell; 2013. p. 375.
Vissing J, Haller RG. A diagnostic cycle test for McArdle’s disease. Ann Neurol. 2003;54(4):539–42.
Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing J. A nonischemic forearm exercise test for McArdle disease. Ann Neurol. 2002;52(2):153–9.
DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve. 2001;24(8):984–99.
Malfatti E, Birouk N, Romero NB, Piraud M, Petit FM, Hogrel JY, et al. Juvenile-onset permanent weakness in muscle phosphofructokinase deficiency. J Neurol Sci. 2012;316(1–2):173–7.
Musumeci O, Bruno C, Mongini T, Rodolico C, Aguennouz M, Barca E, et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012;22(4):325–30.
Kreuder J, Borkhardt A, Repp R, Pekrun A, Göttsche B, Gottschalk U, et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med. 1996;334(17):1100–4.
Yao DC, Tolan DR, Murray MF, Harris DJ, Darras BT, Geva A, et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood. 2004;103(6):2401–3.
Mamoune A, Bahuau M, Hamel Y, Serre V, Pelosi M, Habarou F, et al. A thermolabile aldolase a mutant causes fever-induced recurrent rhabdomyolysis without hemolytic anemia. PLoS Genet. 2014;10(11):e1004711.
Kopp A, Bistrian BR. Inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med. 1996;335(16):1242–3.
Esposito G, Vitagliano L, Cevenini A, Amelio T, Zagari A, Salvatore F. Unraveling the structural and functional features of an aldolase A mutant involved in the hemolytic anemia and severe rhabdomyolysis reported in a child. Blood. 2005;105(2):905–6.
Comi GP, Fortunato F, Lucchiari S, Bordoni A, Prelle A, Jann S, et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol. 2001;50(2):202–7.
Musumeci O, Brady S, Rodolico C, Ciranni A, Montagnese F, Aguennouz M, et al. Recurrent rhabdomyolysis due to muscle β-enolase deficiency: very rare or underestimated? J Neurol. 2014;261(12):2424–8.
Naini A, Toscano A, Musumeci O, Vissing J, Akman HO, DiMauro S. Muscle phosphoglycerate mutase deficiency revisited. Arch Neurol. 2009;66(3):394–8.
Oh SJ, Park KS, Ryan Jr HF, Danon MJ, Lu J, Naini AB, et al. Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency. Muscle Nerve. 2006;34(5):572–6.
Salameh J, Goyal N, Choudry R, Camelo-Piragua S, Chong PS. Phosphoglycerate mutase deficiency with tubular aggregates in a patient from Panama. Muscle Nerve. 2013;47(1):138–40.
Tonin P, Bruno C, Cassandrini D, Savio C, Tavazzi E, Tomelleri G, et al. Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene. Neuromuscul Disord. 2009;19(11):776–8.
Vissing J, Quistorff B, Haller RG. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol. 2005;62(9):1440–3.
DiMauro S, Dalakas M, Miranda AF. Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria. Ann Neurol. 1983;13(1):11–9.
Fermo E, Bianchi P, Chiarelli LR, Maggi M, Mandarà GM, Vercellati C, et al. A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: molecular and functional characterization. Mol Genet Metab. 2012;106(4):455–61.
Rosa R, George C, Fardeau M, Calvin MC, Rapin M, Rosa J. A new case of phosphoglycerate kinase deficiency: PGK Creteil associated with rhabdomyolysis and lacking hemolytic anemia. Blood. 1982;60(1):84–91.
Spiegel R, Gomez EA, Akman HO, Krishna S, Horovitz Y, DiMauro S. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord. 2009;19(3):207–11.
Hamano T, Mutoh T, Sugie H, Koga H, Kuriyama M. Phosphoglycerate kinase deficiency: an adult myopathic form with a novel mutation. Neurology. 2000;54(5):1188–90.
Stojkovic T, Vissing J, Petit F, Piraud M, Orngreen MC, Andersen G, et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009;361(4):425–7.
Marquardt T, Morava E, Rust S. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med. 2014;370(21):2051–2.
Bali DS, Goldstein JL, Fredrickson K, Rehder C, Boney A, Austin S, et al. Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. Mol Genet Metab. 2014;111(3):309–13.
Berg JM, Tymoczko JL, Stryer L. Phosphorylase is regulated by allosteric interactions and reversible phosphorylation. In: Biochemistry. New York: W H Freeman; 2002.
Beauchamp NJ, Dalton A, Ramaswami U, Niinikoski H, Mention K, Kenny P, et al. Glycogen storage disease type IX: high variability in clinical phenotype. Mol Genet Metab. 2007;92(1–2):88–99.
Burwinkel B, Hu B, Schroers A, Clemens PR, Moses SW, Shin YS, et al. Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases. Eur J Hum Genet. 2003;11(7):516–26.
Preisler N, Orngreen MC, Echaniz-Laguna A, Laforet P, Lonsdorfer-Wolf E, Doutreleau S, et al. Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease? Neurology. 2012;78(4):265–8.
Bruno C, Manfredi G, Andreu AL, Shanske S, Krishna S, Ilse WK, et al. A splice junction mutation in the alpha(M) gene of phosphorylase kinase in a patient with myopathy. Biochem Biophys Res Commun. 1998;249(3):648–51.
Wuyts W, Reyniers E, Ceuterick C, Storm K, de Barsy T, Martin JJ, et al. Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A. 2005;133a(1):82–4.
Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med. 2011;26(2):59–72.
Andresen BS, Olpin S, Poorthuis BJ, Scholte HR, Vianey-Saban C, Wanders R, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999;64(2):479–94.
Antunes AP, Nogueira C, Rocha H, Vilarinho L, Evangelista T, et al. Intermittent rhabdomyolysis with adult onset associated with a mutation in the ACADVL gene. J Clin Neuromuscul Dis. 2013;15(2):69–72.
Laforet P, Acquaviva-Bourdain C, Rigal O, Brivet M, Penisson-Besnier I, Chabrol B, et al. Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord. 2009;19(5):324–9.
Ogilvie I, Pourfarzam M, Jackson S, Stockdale C, Bartlett K, Turnbull DM. Very long-chain acyl coenzyme A dehydrogenase deficiency presenting with exercise-induced myoglobinuria. Neurology. 1994;44(3 Pt 1):467–73.
Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 2015;1852(4):615–21.
Fanin M, Anichini A, Cassandrini D, Fiorillo C, Scapolan S, Minetti C, et al. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin Genet. 2012;82(3):232–9.
Liang WC, Nishino I. State of the art in muscle lipid diseases. Acta Myol. 2010;29(2):351–6.
Hogan KJ, Vladutiu GD. Malignant hyperthermia-like syndrome and carnitine palmitoyltransferase II deficiency with heterozygous R503C mutation. Anesth Analg. 2009;109(4):1070–2.
Thuillier L, Rostane H, Droin V, Demaugre F, Brivet M, Kadhom N, et al. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Mutat. 2003;21(5):493–501.
Grunert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis. 2014;9:117.
Izumi R, Suzuki N, Nagata M, Hasegawa T, Abe Y, Saito Y, et al. A case of late onset riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency manifesting as recurrent rhabdomyolysis and acute renal failure. Intern Med. 2011;50(21):2663–8.
Prasad M, Hussain S. Glutaric aciduria type II presenting as myopathy and rhabdomyolysis in a teenager. J Child Neurol. 2015;30(1):96–9.
Rosenbohm A, Süssmuth SD, Kassubek J, Müller HP, Pontes C. Novel ETFDH mutation and imaging findings in an adult with glutaric aciduria type II. Muscle Nerve. 2014;49(3):446–50.
Schiff M, Froissart R, Olsen RK, Acquaviva C, Vianey-Saban C. Electron transfer flavoprotein deficiency: functional and molecular aspects. Mol Genet Metab. 2006;88(2):153–8.
Ronchi D, Garone C, Bordoni A, Gutierrez Rios P, Calvo SE, Ripolone M, et al. Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. Brain. 2012;135(Pt 11):3404–15.
Andreu AL, Bruno C, Dunne TC, Tanji K, Shanske S, Sue CM, et al. A nonsense mutation (G15059A) in the cytochrome b gene in a patient with exercise intolerance and myoglobinuria. Ann Neurol. 1999;45(1):127–30.
Andreu AL, Hanna MG, Reichmann H, Bruno C, Penn AS, Tanji K, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med. 1999;341(14):1037–44.
Greenstein P, Sue CM, Joseph JT, Tanji K, Haller RG, et al. Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. Neurology. 2000;55(5):644–9.
Hoffbuhr KC, Burton MD, Salas VM, Johnston WS, Penn AM, et al. A microdeletion in cytochrome c oxidase (COX) subunit III associated with COX deficiency and recurrent myoglobinuria. Nat Genet. 1996;12(4):410–6.
Kollberg G, Melberg A, Holme E, Oldfors A. Transient restoration of succinate dehydrogenase activity after rhabdomyolysis in iron-sulphur cluster deficiency myopathy. Neuromuscul Disord. 2011;21(2):115–20.
Liewluck T, Mundi MS, Mauermann ML. Mitochondrial trifunctional protein deficiency: a rare cause of adult-onset rhabdomyolysis. Muscle Nerve. 2013;48(6):989–91.
Marotta R, Chin J, Kirby DM, Chiotis M, Cook M, Collins SJ. Novel single base pair COX III subunit deletion of mitochondrial DNA associated with rhabdomyolysis. J Clin Neurosci. 2011;18(2):290–2.
McFarland R, Taylor RW, Chinnery PF, Howell N, Turnbull DM, et al. A novel sporadic mutation in cytochrome c oxidase subunit II as a cause of rhabdomyolysis. Neuromuscul Disord. 2004;14(2):162–6.
Vissing CR, Duno M, Olesen JH, Rafiq J, Risom L, Christensen E, et al. Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene. Neurology. 2013;80(20):1908–10.
Vanlander AV, Jorens PG, Smet J, De Paepe B, Verbrugghe W, Van den Eynden GG, et al. Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome. Acta Anaesthesiol Scand. 2012;56(4):520–5.
Savard M, Dupré N, Turgeon AF, Desbiens R, Langevin S, Brunet D. Propofol-related infusion syndrome heralding a mitochondrial disease: case report. Neurology. 2013;81(8):770–1.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
Jungbluth H, Sewry CA, Muntoni F. Core myopathies. Semin Pediatr Neurol. 2011;18(4):239–49.
Jungbluth H, Zhou H, Hartley L, Halliger-Keller B, Messina S, Longman C, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology. 2005;65(12):1930–5.
Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol. 2010;68(5):717–26.
Clarke NF, Waddell LB, Cooper ST, Perry M, Smith RL, Kornberg AJ, et al. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum Mutat. 2010;31(7):E1544–50.
Dowling JJ, Lillis S, Amburgey K, Zhou H, Al-Sarraj S, Buk SJ, et al. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord. 2011;21(6):420–7.
Loseth S, Voermans NC, Torbergsen T, Lillis S, Jonsrud C, Lindal S, et al. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. J Neurol. 2013;260(6):1504–10.
Carsana A. Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations. Sci World J. 2013;2013:531465.
Lindberg C, Sixt C, Oldfors A. Episodes of exercise-induced dark urine and myalgia in LGMD 2I. Acta Neurol Scand. 2012;125(4):285–7.
Ceravolo F, Messina S, Rodolico C, Strisciuglio P, Concolino D. Myoglobinuria as first clinical sign of a primary alpha-sarcoglycanopathy. Eur J Pediatr. 2014;173(2):239–42.
Moody S, Mancias P. Dysferlinopathy presenting as rhabdomyolysis and acute renal failure. J Child Neurol. 2013;28(4):502–5.
Lahoria R, Winder TL, Lui J, Al-Owain MA, Milone M. Novel ANO5 homozygous microdeletion causing myalgia and unprovoked rhabdomyolysis in an Arabic man. Muscle Nerve. 2014;50(4):610–3.
Milone M, Liewluck T, Winder TL, Pianosi PT. Amyloidosis and exercise intolerance in ANO5 muscular dystrophy. Neuromuscul Disord. 2012;22(1):13–5.
Cagliani R, Comi GP, Tancredi L, Sironi M, Fortunato F, Giorda R, et al. Primary beta-sarcoglycanopathy manifesting as recurrent exercise-induced myoglobinuria. Neuromuscul Disord. 2001;11(4):389–94.
Mathews KD, Stephan CM, Laubenthal K, Winder TL, Michele DE, Moore SA, et al. Myoglobinuria and muscle pain are common in patients with limb-girdle muscular dystrophy 2I. Neurology. 2011;76(2):194–5.
Nakazato A, Shime H, Morooka K, Nonaka I, Takagi A. Anesthesia-induced rhabdomyolysis in a patient with Fukuyama-type congenital muscular dystrophy. No To Hattatsu. 1984;16(5):386–92.
Veyckemans F. Can inhalation agents be used in the presence of a child with myopathy? Curr Opin Anaesthesiol. 2010;23(3):348–55.
Michot C, Hubert L, Brivet M, De Meirleir L, Valayannopoulos V, Müller-Felber W, et al. LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood. Hum Mutat. 2010;31(7):E1564–73.
Michot C, Hubert L, Romero NB, Gouda A, Mamoune A, Mathew S, et al. Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis. 2012;35(6):1119–28.
Bergounioux J, Brassier A, Rambaud C, Bustarret O, Michot C, Hubert L, et al. Fatal rhabdomyolysis in 2 children with LPIN1 mutations. J Pediatr. 2012;160(6):1052–4.
Zeharia A, Shaag A, Houtkooper RH, Hindi T, de Lonlay P, Erez G, et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet. 2008;83(4):489–94.
Muller-Felber W, Zafiriou D, Scheck R, Pätzke I, Toepfer M, Pongratz DE, et al. Marinesco Sjogren syndrome with rhabdomyolysis. A new subtype of the disease. Neuropediatrics. 1998;29(2):97–101.
Superneau DW, Wertelecki W, Zellweger H, Bastian F. Myopathy in Marinesco-Sjogren syndrome. Eur Neurol. 1987;26(1):8–16.
Merlini L, Gooding R, Lochmüller H, Müller-Felber W, Walter MC, Angelicheva D, et al. Genetic identity of Marinesco-Sjogren/myoglobinuria and CCFDN syndromes. Neurology. 2002;58(2):231–6.
Barth PG, Ryan MM, Webster RI, Aronica E, Kan A, Ramkema M, et al. Rhabdomyolysis in pontocerebellar hypoplasia type 2 (PCH-2). Neuromuscul Disord. 2008;18(1):52–8.
Zafeiriou DI, Ververi A, Tsitlakidou A, Anastasiou A, Vargiami E. Recurrent episodes of rhabdomyolysis in pontocerebellar hypoplasia type 2. Neuromuscul Disord. 2013;23(2):116–9.
Deuster PA, Contreras-Sesvold CL, O’Connor FG, Campbell WW, Kenney K, Capacchione JF, et al. Genetic polymorphisms associated with exertional rhabdomyolysis. Eur J Appl Physiol. 2013;113(8):1997–2004.
Heled Y, Bloom MS, Wu TJ, Stephens Q, Deuster PA, et al. CK-MM and ACE genotypes and physiological prediction of the creatine kinase response to exercise. J Appl Physiol (1985). 2007;103(2):504–10.
Yamin C, Amir O, Sagiv M, Attias E, Meckel Y, Eynon N, et al. ACE ID genotype affects blood creatine kinase response to eccentric exercise. J Appl Physiol (1985). 2007;103(6):2057–61.
Orysiak J, Sitkowski D, Zmijewski P, Malczewska-Lenczowska J, Cieszczyk P, Zembron-Lacny A, et al. Overrepresentation of the ACTN3 XX genotype in elite canoe and kayak paddlers. J Strength Cond Res. 2015;29(4):1107–12.
Clarkson PM, Hoffman EP, Zambraski E, Gordish-Dressman H, Kearns A, Hubal M, et al. ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol (1985). 2005;99(2):564–9.
Devaney JM, Hoffman EP, Gordish-Dressman H, Kearns A, Zambraski E, Clarkson PM. IGF-II gene region polymorphisms related to exertional muscle damage. J Appl Physiol (1985). 2007;102(5):1815–23.
Hubal MJ, Devaney JM, Hoffman EP, Zambraski EJ, Gordish-Dressman H, Kearns AK, et al. CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage. J Appl Physiol (1985). 2010;108(6):1651–8.
Yamin C, Duarte JA, Oliveira JM, Amir O, Sagiv M, Eynon N, et al. IL6 (−174) and TNFA (−308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise. Eur J Appl Physiol. 2008;104(3):579–86.
Cabrera M, Ghaoui R, Mourdant D, Lamont PJ, Clarke N, Laing NG. T.P.33. Clinical and genetic characterization of patients with repeated rhabdomyolysis. Neuromuscul Disord. 2014;24(9):874.
Scalco RS, Pitceathly RDS, Gardiner A, Woodward C, Polke JM, Sweeney MG, et al. G.P.22. Utilising next-generation sequencing to determine the genetic basis of recurrent rhabdomyolysis. Neuromuscul Disord. 2014;24(9):801.
Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur J Intern Med. 2007;18(2):90–100.
Jhawar M, George P, Pawar B. Salmonella typhi sepsis and rhabdomyolysis with acute renal failure: a rare presentation of a common disease. Saudi J Kidney Dis Transpl. 2010;21(4):732–4.
Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67(9):272–83.
Toprak O, Kaptan F, Cirit M, Ormen B, Uzum A, Ersoy R, et al. Recurrent rhabdomyolysis and mild acute renal failure associated with acute Brucella infection. Nephrol Dial Transplant. 2005;20(4):848–9.
Spiegel R, Saada A, Halvardson J, Soiferman D, Shaag A, Edvardson S, et al. Deleterious mutation in FDX1L gene is associated with a novel mitochondrial muscle myopathy. Eur J Hum Genet. 2014;22(7):902–6.
The authors would like to thank NHS England, Association for Glycogen Storage Disease (AGSD), CAPES Foundation and the European Union for funding.
The authors declare that they have no competing interests.
RSS initiated and executed the review, performed the literature search and drafted the manuscript. RSS was jointly supervised by RQ and HJ. The remaining authors reviewed and revised the manuscript. All authors read and approved the final manuscript.
Heinz Jungbluth and Ros Quinlivan both authors jointly supervised the review.
About this article
Cite this article
Scalco, R.S., Gardiner, A.R., Pitceathly, R.D. et al. Rhabdomyolysis: a genetic perspective. Orphanet J Rare Dis 10, 51 (2015). https://doi.org/10.1186/s13023-015-0264-3
- Neuromuscular disorders
- Increased CK
- Muscle metabolism
- Muscle Biopsy